China Food and Drug Administration (CFDA) has become a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
ICH, set up by the US, Europe and Japan in 1990, is an international organization that standardizes global drug registrations and manufacturing practices.
Its mission is to ensure safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner.
Acceptance of the CFDA by the organization means China's drug regulation is now in line with international standards and this has boosted the hope of selling Chinese pharmaceutical products abroad.
Yuan Lin, director general of CFDA's Department of International Cooperation, said, "This marks a milestone in the history of China's pharmaceutical development history."
He stated that it showed CFDA's ongoing reform of drug review and approval has received recognition from the international community.
In the future, Chinese patients are likely to have corresponding access to new medicines as patients in other countries, which will in turn promote Chinese pharmaceutical companies' innovation capabilities and international competitiveness.